Home Cart Sign in  
Chemical Structure| 29342-05-0 Chemical Structure| 29342-05-0

Structure of Ciclopirox
CAS No.: 29342-05-0

Chemical Structure| 29342-05-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ciclopirox inhibits iron-dependent enzymes PHD2 (pIC50 = 5.8) and deoxyhypusine hydroxylase. It is an antifungal and iron-chelating agent.

Synonyms: HOE296b; Penlac

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ciclopirox

CAS No. :29342-05-0
Formula : C12H17NO2
M.W : 207.27
SMILES Code : O=C1C=C(C)C=C(C2CCCCC2)N1O
Synonyms :
HOE296b; Penlac
MDL No. :MFCD00599441
InChI Key :SCKYRAXSEDYPSA-UHFFFAOYSA-N
Pubchem ID :2749

Safety of Ciclopirox

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Ciclopirox

epigenetics

Isoform Comparison

Biological Activity

Target
  • ATPase

In Vitro:

Cell Line
Concentration Treated Time Description References
NB-1691 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival Cancer Res. 2017 Sep 1;77(17):4626-4638.
SK-N-SH 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival Cancer Res. 2017 Sep 1;77(17):4626-4638.
IMR-32 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival Cancer Res. 2017 Sep 1;77(17):4626-4638.
SK-N-AS 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival Cancer Res. 2017 Sep 1;77(17):4626-4638.
HEK293T 5-10 μmol/L 48 hours To screen small-molecule compounds that promote NP degradation, results showed that Ciclopirox significantly reduced NP expression. Acta Pharm Sin B. 2024 Jun;14(6):2505-2519.
Huh-7 cells 1μM 36 hours Evaluating the effect of Ciclopirox on intracellular HBV capsid assembly, finding it inhibits HBV capsid assembly. Nat Commun. 2019 May 16;10(1):2184.
HepG2.2.15 cells 1μM 3 days Screening compounds for HBV replication inhibition, finding that Ciclopirox significantly inhibits HBV DNA secretion. Nat Commun. 2019 May 16;10(1):2184.
HS68 5 µM 4 days No significant effect on the viability of the normal human fibroblast cell line HS68 Cancer Res. 2017 Sep 1;77(17):4626-4638.
BE(2)-C 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival, induced cell morphology changes such as neurite outgrowth Cancer Res. 2017 Sep 1;77(17):4626-4638.
SW480 20 μM 24 hours To evaluate the effect of CPX on CRC cell proliferation and apoptosis, results showed that CPX significantly inhibited CRC cell proliferation and induced apoptosis. Theranostics. 2019 Jul 28;9(19):5577-5594.
HCT116 20 μM 24 hours To evaluate the effect of CPX on CRC cell proliferation and apoptosis, results showed that CPX significantly inhibited CRC cell proliferation and induced apoptosis. Theranostics. 2019 Jul 28;9(19):5577-5594.
PANC1 cells 5 μM 72 hours Inhibited cell proliferation and eIF5A1 hypusination Cancer Res. 2014 Nov 15;74(22):6671-81.
FG cells 5 μM 72 hours Inhibited cell proliferation and eIF5A1 hypusination Cancer Res. 2014 Nov 15;74(22):6671-81.
SiHa cells 20 μM 24 hours To evaluate the inhibitory effect of CPX on the proliferation of cervical cancer cells. Results showed that CPX treatment significantly inhibited the proliferation of SiHa cells. Redox Biol. 2022 Jul;53:102339.
HeLa cells 20 μM 24 hours To evaluate the inhibitory effect of CPX on the proliferation of cervical cancer cells. Results showed that CPX treatment significantly inhibited the proliferation of HeLa cells. Redox Biol. 2022 Jul;53:102339.
Calu-3 2.8 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. Acta Pharm Sin B. 2024 Jun;14(6):2505-2519.
HeLa-ACE2 1.7 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. Acta Pharm Sin B. 2024 Jun;14(6):2505-2519.
Vero-E6 1.3 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. Acta Pharm Sin B. 2024 Jun;14(6):2505-2519.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SD rats Middle cerebral artery occlusion (MCAO) model Intravenous injection 3 mg/kg Single or multiple doses, lasting for 7 days Evaluate the alleviating effect of CPX on brain infarction, neurological deficits and brain edema Acta Pharm Sin B. 2020 Mar;10(3):434-446
SCID mice Neuroblastoma disseminated disease model Subcutaneous pump continuous release 12 mg/ml Continuous for 4 weeks CPX significantly reduced tumor burden and inhibited or prevented disease dissemination Cancer Res. 2017 Sep 1;77(17):4626-4638.
Nude mice HCT116 xenograft model Oral gavage 25 mg/kg Once daily for three weeks To evaluate the antitumor effect of CPX in vivo, results showed that CPX significantly inhibited tumor growth. Theranostics. 2019 Jul 28;9(19):5577-5594.
C57BL/6 mice MOC2-E6/E7 subcutaneous xenograft model Intraperitoneal injection 10 mg/kg and 15 mg/kg Once or twice daily for 21 days To evaluate the inhibitory effect of Ciclopirox on tumor growth in vivo. The results showed that SC144 significantly delayed tumor growth, while the effect of CPX was not significant. Theranostics. 2020 May 25;10(15):6959-6976
BALB/C mice SARS-CoV-2 infection model Intraperitoneal injection 20 mg/kg/day Once daily for 5 days To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication in vivo, results showed that Ciclopirox significantly reduced viral titers and lung pathology. Acta Pharm Sin B. 2024 Jun;14(6):2505-2519.
PXB mice (humanized liver mouse model) HBV infection model Oral 5 mg/kg Once daily for 5 weeks Evaluating the inhibitory effect of Ciclopirox on HBV replication in vivo, finding it significantly reduces serum HBV DNA levels. Nat Commun. 2019 May 16;10(1):2184.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00382330 Vulvar Cancer WITHDRAWN - University of Medicine and Den... More >>tistry of NJ, Newark, New Jersey, 07107, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.82mL

0.96mL

0.48mL

24.12mL

4.82mL

2.41mL

48.25mL

9.65mL

4.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories